Dr. Figueroa is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Medical Oncology Consultants 7503 Norfolk Avenue
Lubbock, TX 79423Phone+1 806-790-8817Fax+1 806-606-0672
Summary
- Dr. Jose A. Figueroa is an American Board of Internal Medicine Certified Medical Oncologist and Clinical Researcher. He received his medical degree from the University of Puerto Rico School of Medicine in 1987 and completed his sub-specialty in Medical Oncology and Translational Research at the UTHSC-San Antonio, TX in 1993. Dr. Figueroa is an expert Dr Figueroa is an expert in chemotherapy, cancer immunotherapy and clinical cancer research and specializes in the treatment of patients afflicted with solid malignancies, including breast cancer, gastrointestinal cancer, gynecologic cancer, and thoracic cancer. He is also a founding member and former Chief Medical Officer of KiromicBiopharma, Inc, a start-up biotech company focused in immune target discovery and development of targeted cancer vaccines and engineered cellular (T-cell and NK cells) therapies.
Education & Training
- University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 1990 - 1993
- VA Caribbean Healthcare SystemResidency, Internal Medicine, 1987 - 1990
- University of Puerto Rico School of MedicineClass of 1987
- University of Puerto Rico, Mayaguez CampusBSc, Biology, Magna Cum Laude, 1983
Certifications & Licensure
- TX State Medical License 1994 - 2025
- NM State Medical License 2005 - 2018
- OK State Medical License 1993 - 1994
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Outstanding Clerkship Medical Student Educator Texas Tech University Health Sciences Center-School of Medicine, 2014
- Excellence in Patient Care and Satisfaction Southwest Cancer Center, 2014
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
- Join now to see all
Clinical Trials
- Therapy for Progressive and/or Refractory Hematologic Malignancies Start of enrollment: 2017 Jul 28
- Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies Start of enrollment: 2017 Jul 28
- Consolidation Therapy in Patients With Metastatic Solid Malignancies Start of enrollment: 2017 Jul 28
- Join now to see all
Publications & Presentations
PubMed
- 14 citationsA Phase I and Pharmocokinetic Study of Exatecan Mesylate Administered as a Protracted 21-Day Infusion in Patients with Advanced Solid MalignanciesMitchell Garrison, Lisa A. Hammond, Charles E. Geyer, Garry Schwartz, Anthony W. Tolcher
Clinical Cancer Research. 2003-07-01 - 83 citationsExpression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor statusJose A. Figueroa, James G. Jackson, William L. McGuire, Robert F. Krywicki, Douglas Yee
Journal of Cellular Biochemistry. 1993-06-01 - 83 citationsCorrelation of Insulin-Like Growth Factor-Binding Protein-3 Messenger RNA With Protein Expression in Primary Breast Cancer Tissues: Detection of Higher Levels in Tumor...Rafael L. Rocha, Susan G. Hilsenbeck, James G. Jackson, Adrian V. Lee, José A. Figueroa
Journal of the National Cancer Institute. 1996-05-01
Journal Articles
- Novel Antigens in Non-small Cell Lung Cancer: SP17, AKAP4, and PTTG1 Are Potential Immunotherapeutic TargetsMirandola L, Figueroa JA, Phan T, et al., Oncotarget, 1/1/2015
- Galectin-3 Inhibition Suppresses Drug Resistance, Motility, Invasion and Angiogenic Potential in Ovarian CancerMirandola L, Yu Y, Cannon MJ, Jenkins MR, Rahman RL, Nguyen DD, Grizzi F, Cobos E, Figueroa JA, Chiriva-Internati M, Gynecologic Oncology
- Chimeric Antigen Receptor Engineering: A Right Step in the Evolution of Adoptive Cellular ImmunotherapyFigueroa JA, Reidy A, Mirandola L, Trotter K, Suvorava N, Figueroa A, Konala V, Aulakh A, Littlefield L, Grizzi F, Rahman R, Jenkins M, Musgrove B, Radhi S, D'Cunha N,..., Int Rev Immuno, 1/1/2015
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- SP17 as a new immunotherapy target and biomarker for triple negative breast cancer.Chiriva-Internati M, Mirandola L, Cobos E, dahlbeck S, Nguyen D, Figueroa JA, Rahman RL, Immunology, 1/1/2015
- High-dose-rate brachytherapy as monotherapy for favorable-risk adenocarcinoma of the prostate delivered in a single 19 Gy fraction: Preliminary results of a prospectiv...Dahlbeck, Scott, Chase C. Hansen, A. Robert Kagan, Carlos Torres, Maurizio Chiriva-Internati, Everardo Cobos, Jose A. Figueroa, Diane Nguyen, Lukman Tijani, and Jaden ..., Cancer Research, 1/1/2015
- Cancer Testes Antigens: Potential New targets for Lung Cancer.Leonardo Mirandola, Jehanzeb Riaz, Rashmi Verma, Saba Radhi, Teresia Pham, Amardeep Aulakh, Venu Konala, Yuefei Yu, Fred Hardwick, Lukman Aderoju Tijani, Nicholas C. D..., J Clin Oncol, 1/1/2014
- Join now to see all
Lectures
- SP17 as a New Immunotherapy Target and Biomarker for Triple Negative Breast Cancer1/1/2015
- Translational Research Conference: Cell Cycle Regulation1/1/2014
- Clinical Research Conference (Monthly)1/1/2014
- Join now to see all
Professional Memberships
- Member
Other Languages
- Spanish
External Links
- Kiromic, Inchttp://Kiromic.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: